June 10, 2022
Life Sciences
  • The House passed a bill to reauthorize drug industry fees to help fund the Food and Drug Administration (FDA) for the next five years. The package includes measures to overhaul the agency’s accelerated approval process, increase diversity in clinical trials and address pediatric cancer research. However, the House-passed bill differs from the Senate’s proposal and lawmakers haven’t yet said how they’ll reconcile the two versions of the must-pass legislation. They aim to pass the legislation before the August recess. (Press release here; Article here)